DURECT CORPORATION (NASDAQ:DRRX) Files An 8-K Other Events

DURECT CORPORATION (NASDAQ:DRRX) Files An 8-K Other Events

Story continues below

Item 8.01 Other Events

On June 22, 2017, DURECT Corporation, a Delaware corporation
(DURECT), issued a press release announcing that patient
enrollment has been completed in PERSIST, the pivotal Phase 3
clinical trial of POSIMIR (SABER-Bupivacaine), an investigational
locally acting, non-opioid analgesic intended to provide up to
three days of continuous pain relief after surgery. A copy of
DURECTs press release is attached as Exhibit 99.1 hereto and
incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1

Press Release of DURECT Corporation dated June 22, 2017



DURECT CORP Exhibit
EX-99.1 2 drrx-ex991_6.htm EX-99.1 drrx-ex991_6.htm   Exhibit 99.1   DURECT Completes Enrollment in PERSIST,…
To view the full exhibit click here
About DURECT CORPORATION (NASDAQ:DRRX)

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company’s ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

An ad to help with our costs